Fig. 5

MUC20 increases CDKN2A expression through inhibiting MET activation in proteasome inhibitor-resistant MM cells. A Representative image of Co-IP using a MET antibody in PI-resistant KAS-6/1 and U266 cells. Rabbit IgG was used as negative control. B Representative image of Co-IP using a MET antibody in control or MUC20 OE-transfected PI-resistant KAS-6/1 and U266 cells. Rabbit IgG was used as negative control. C MET and pMET levels in control or MUC20 OE-transfected PI-resistant KAS-6/1 and U266 cells. D Representative image of Co-IP using a His antibody in WT-MET or MUT-MET-transfected PI-resistant KAS-6/1 and U266 cells. Rabbit IgG was used as negative control. E CDKN2A and pCDKN2A levels in control or MUC20 OE/CDKN2A OE-transfected PI-resistant KAS-6/1 and U266 cells. F CDKN2A and pCDKN2A levels in PI-resistant KAS-6/1 and U266 cells treated with or without phosphatase inhibitor cocktail I. PR: proteasome inhibitor-resistant MM cells; OE: overexpression; PIC I: phosphatase inhibitor cocktail I. *P < 0.05, **P < 0.01